NICE recommends cabozantinib for advanced renal cell cancer
The National Institute for Health and Care Excellence (NICE) has issued final guidance recommending cabozantinib for some kidney cancer patients
List view / Grid view
News
Mindfulness-based therapy may reduce stress in obese patients
In a randomised clinical trial of women who were overweight or obese, mindfulness-based stress reduction (MBSR) increased mindfulness and decreased stress compared with health education.
Vitamin D may improve sunburn, says new trial
High doses of vitamin D taken one hour after sunburn significantly reduce skin redness, swelling, and inflammation, according to double-blinded, placebo-controlled clinical trial out of Case Western Reserve University School of Medicine and University Hospitals Cleveland Medical Center. Study specifics In the study, 20 participants were randomised to receive a…
Brain training app improves memory in people with cognitive impairment
A brain training game could help improve the memory of patients in the very earliest stages of dementia, suggests a study.
Novartis combination targeted therapy receives FDA approval
The FDA has approved Novartis’ Tafinlar (dabrafenib) in combination with Mekinist (trametinib) to treat patients with metastatic non-small cell lung cancer.
Study predicts 1.2 million people in UK will be living with dementia by 2040
By 2040, there will be over 1.2 million people living with dementia in England and Wales (an increase of 57% from 2016), due to increased life expectancy...
Wickham Laboratories now offering full suite of medical device biocompatibility and safety testing
Wickham Laboratories is pleased to announce the extension of its medical device testing services...
Heart failure market worth $16 billion by 2026 as Novartis’ drug triggers growth
The heart failure space across the seven key markets of the US, France, Germany, Italy, Spain, the UK and Japan is set to grow from $3.7 billion in 2016 to around $16.1 billion by 2026, representing an impressive compound annual growth rate of 15.7%, according to research and consulting firm…
Patheon to invest $45 million in spray drying & manufacturing solutions
Patheon expects to invest approximately $45 million at key sites across its network in spray drying capabilities and flexible manufacturing solutions...
ABPI respond to statement of UK Government’s medicines regulation plans
The ABPI has responded to a joint letter from Jeremy Hunt, Secretary of State for Health, and Greg Clark, Secretary of State for Business, published by the Financial Times, that outlined the UK Government’s plans for the regulation of medicines as the UK leaves the European Union (EU).
NICE recommends Lilly’s Baricitinib (Olumiant) to treat rheumatoid arthritis
Baricitinib is the first JAK inhibitor to be recommended by NICE to treat rheumatoid arthritis in adults who have not responded to conventional therapy…
Sandoz receives EU approval in Europe for Rixathon (biosimilar rituximab)
The EC has approved Sandoz’ Rixathon (biosimilar rituximab) for use in Europe. Rixathon is approved for use in all indications of the reference medicine...
NICE approves AstraZeneca’s COPD drug
The National Institute for Health and Care Excellence (NICE) has published draft guidance recommending roflumilast (Daxas, AstraZeneca) for chronic obstructive pulmonary disease (COPD).
Steven Baertschi joins EPR advisory board
Dr Steven Baertschi has joined the editorial advisory board of European Pharmaceutical Review.
Fujifilm Diosynth Biotechnologies announce successful completion of its 100th paveway
Fujifilm Diosynth Biotechnologies has announced the successful completion of its 100th program using its pAVEway™ Advanced Protein Expression system...
